177 related articles for article (PubMed ID: 30368414)
1. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Dagogo-Jack I; Stevens SE; Lin JJ; Nagy R; Ferris L; Shaw AT; Gainor JF
J Thorac Oncol; 2018 Nov; 13(11):e226-e227. PubMed ID: 30368414
[No Abstract] [Full Text] [Related]
2. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Lee SH; Lee JK; Ahn MJ; Kim DW; Sun JM; Keam B; Kim TM; Heo DS; Ahn JS; Choi YL; Min HS; Jeon YK; Park K
Ann Oncol; 2017 Feb; 28(2):292-297. PubMed ID: 27803005
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
4. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A; Morten J; Ji Q; Elvin P; Womack C; Su X; Donald E; Gray N; Read J; Bigley G; Blockley L; Cresswell C; Dale A; Davies A; Zhang T; Fan S; Fu H; Gladwin A; Harrod G; Stevens J; Williams V; Ye Q; Zheng L; de Boer R; Herbst RS; Lee JS; Vasselli J
BMC Cancer; 2015 Mar; 15():171. PubMed ID: 25881079
[TBL] [Abstract][Full Text] [Related]
6. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Falchook GS; Ordóñez NG; Bastida CC; Stephens PJ; Miller VA; Gaido L; Jackson T; Karp DD
J Clin Oncol; 2016 May; 34(15):e141-4. PubMed ID: 25366691
[No Abstract] [Full Text] [Related]
7. RET-rearranged non-small-cell lung cancer and therapeutic implications.
Loh Z; Mitchell P; John T; Arulananda S
Intern Med J; 2019 Dec; 49(12):1541-1545. PubMed ID: 31808254
[TBL] [Abstract][Full Text] [Related]
8. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
9. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
[TBL] [Abstract][Full Text] [Related]
10. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Takeda H; Takigawa N; Ohashi K; Minami D; Kataoka I; Ichihara E; Ochi N; Tanimoto M; Kiura K
Exp Cell Res; 2013 Feb; 319(4):417-23. PubMed ID: 23274758
[TBL] [Abstract][Full Text] [Related]
11. Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Nosaki K; Kohno T; Tsuta K; Nomura S; Ikeno T; Wakabayashi M; Sato A; Matsumoto S; Goto K
Lung Cancer; 2021 May; 155():40-45. PubMed ID: 33725547
[TBL] [Abstract][Full Text] [Related]
12. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
13. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
14. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
[TBL] [Abstract][Full Text] [Related]
17. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
Velcheti V; Madison R; Ali SM; Schrock AB
J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
[No Abstract] [Full Text] [Related]
18. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
19. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
